U.S. markets closed
  • S&P Futures

    3,839.00
    -3.50 (-0.09%)
     
  • Dow Futures

    30,786.00
    -56.00 (-0.18%)
     
  • Nasdaq Futures

    13,546.75
    +61.25 (+0.45%)
     
  • Russell 2000 Futures

    2,136.40
    -9.40 (-0.44%)
     
  • Crude Oil

    52.85
    +0.24 (+0.46%)
     
  • Gold

    1,843.80
    -7.10 (-0.38%)
     
  • Silver

    25.35
    -0.18 (-0.72%)
     
  • EUR/USD

    1.2161
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    23.02
    -0.17 (-0.73%)
     
  • GBP/USD

    1.3729
    -0.0003 (-0.02%)
     
  • USD/JPY

    103.7260
    +0.0990 (+0.10%)
     
  • BTC-USD

    31,713.25
    -647.45 (-2.00%)
     
  • CMC Crypto 200

    638.84
    -8.48 (-1.31%)
     
  • FTSE 100

    6,654.01
    +15.16 (+0.23%)
     
  • Nikkei 225

    28,636.08
    +89.90 (+0.31%)
     

CLASS ACTION UPDATE for ICPT, LRN and BRY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

·4 min read

NEW YORK, NY / ACCESSWIRE / December 30, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ICPT Shareholders Click Here: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11872&wire=1
LRN Shareholders Click Here: https://www.zlk.com/pslra-1/k12inc-information-request-form?prid=11872&wire=1
BRY Shareholders Click Here: https://www.zlk.com/pslra-1/berry-corporation-loss-submission-form?prid=11872&wire=1

* ADDITIONAL INFORMATION BELOW *

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

ICPT Lawsuit on behalf of: investors who purchased September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline: January 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11872&wire=1

According to the filed complaint, during the class period, Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

K12 Inc. (NYSE:LRN)

LRN Lawsuit on behalf of: investors who purchased April 27, 2020 - September 18, 2020
Lead Plaintiff Deadline: January 19, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/k12inc-information-request-form?prid=11872&wire=1

According to the filed complaint, during the class period, K12 Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) K12 lacked the technological capabilities, infrastructures, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (ii) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer system; (iii) K12 was unable provide the necessary levels of administrative support and training to teachers, students, and parents; and (iv) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and prospects and/or lacked a reasonable basis and omitted facts.

Berry Corporation (NASDAQ:BRY)

Lawsuit on behalf of investors who purchased: (a) Berry common stock pursuant and/or traceable to the Company's initial public offering conducted on or about July 26, 2018; or (b) Berry securities between July 26, 2018 and November 3, 2020, both dates inclusive
Lead Plaintiff Deadline: January 21, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/berry-corporation-loss-submission-form?prid=11872&wire=1

According to the filed complaint, (i) Berry had materially overstated its operational efficiency and stability; (ii) Berry's operational inefficiency and instability would foreseeably necessitate operational improvements that would disrupt the Company's productivity and increase costs; (iii) the foregoing would foreseeably negatively impact the Company's revenues; and (iv) as a result, the Offering Documents and the Company's public statements were materially false and/or misleading and failed to state information required to be stated therein.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
http://www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/622696/CLASS-ACTION-UPDATE-for-ICPT-LRN-and-BRY-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders